TCR-T targeting MAGE-A3 has reported lethal off-target cross-reactivity in clinical trials because of the high affinity of the TCR combined with the tumor pMHC (peptide-major histocompatibility complex) 19-21. Here, MAGEA3 is linked to neoplasm.